SCHEMBL3341887

SCHEMBL3341887

CC/C=C/C(=O)CCc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 2/20 0.72
TRPV1 Q8NER1 1/20 0.56
ALDH1A1 P00352 1/20 0.53
KEAP1 Q14145 1/20 0.52
ALOX5 P09917 2/20 0.51
FFAR1 O14842 1/20 0.48
MAPT P10636 2/20 0.47
HTT P42858 1/20 0.47
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HDAC1 Q13547 2/20 0.45
KMT2A Q03164 1/20 0.45
EPHX2 P34913 1/20 0.45
HDAC3 O15379 1/20 0.44
MAPK1 P28482 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC4 P56524 1/20 0.44
SLC6A3 Q01959 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341890 1.00 GPR52 (0.72) GPR52TRPV1ALDH1A1KEAP1ALOX5
SCHEMBL20661175 0.84 TRPV1 (0.58) GPR52TRPV1ALDH1A1ALOX5MAPT
SCHEMBL28514524 0.84 TRPV1 (0.58) GPR52TRPV1ALDH1A1ALOX5MAPT
SCHEMBL7426203 0.84 GPR52 (0.74) GPR52TRPV1ALDH1A1KEAP1ALOX5
SCHEMBL7426208 0.84 GPR52 (0.74) GPR52TRPV1ALDH1A1KEAP1ALOX5
SCHEMBL6373067 0.84 GPR52 (1.00) GPR52TRPV1KEAP1ALOX5
SCHEMBL6373065 0.84 GPR52 (1.00) GPR52TRPV1KEAP1ALOX5
SCHEMBL7297626 0.82 GPR52 (0.71) GPR52TRPV1ALOX5EPHX2SMN1; SMN2
SCHEMBL7297630 0.82 GPR52 (0.71) GPR52TRPV1ALOX5EPHX2SMN1; SMN2
SCHEMBL8733597 0.81 CES1 (0.48) GPR52ALDH1A1MAPTHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250041408-A1 SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY THE UNIVERSITY OF CHICAGO 2025-02-06 US disclosed
US-11540539-B2 Reduced sodium food products GENERAL MILLS, INC. (US) 2023-01-03 US disclosed
US-20200281236-A1 REDUCED SODIUM FOOD PRODUCTS GEN MILLS INC (US) 2020-09-10 US disclosed
EP-3366677-B1 REDUCED SODIUM FOOD PRODUCTS GEN MILLS INC (US) 2020-09-09 EP disclosed
EP-3466930-A1 REDUCED SODIUM FOOD PRODUCT GENERAL MILLS, INC. (US) 2019-04-10 EP disclosed
US-20190090520-A1 REDUCED SODIUM FOOD PRODUCTS GEN MILLS INC (US) 2019-03-28 US disclosed
EP-2954037-B1 REDUCED SODIUM FOOD PRODUCTS GEN MILLS INC (US) 2018-04-11 EP disclosed
EP-2956440-B1 REDUCED SODIUM FOOD PRODUCTS GEN MILLS INC (US) 2018-04-11 EP disclosed
EP-2953934-B1 REDUCED SODIUM FOOD PRODUCTS GEN MILLS INC (US) 2018-04-11 EP disclosed
US-9561272-B2 Compositions and methods for modulating immune responses THE UNIVERSITY OF QUEENSLAND (AU) 2017-02-07 US disclosed
WO-2014124214-A1 REDUCED SODIUM FOOD PRODUCTS GENERAL MILLS, INC. (US) 2014-08-14 WO disclosed
WO-2014124209-A1 REDUCED SODIUM FOOD PRODUCTS GENERAL MILLS, INC. (US) 2014-08-14 WO disclosed
WO-2014124198-A1 REDUCED SODIUM FOOD PRODUCT GENERAL MILLS, INC. (US) 2014-08-14 WO disclosed
WO-2014124212-A1 REDUCED SODIUM FOOD PRODUCTS GENERAL MILLS, INC. (US) 2014-08-14 WO disclosed
WO-2014124222-A1 REDUCED SODIUM FOOD PRODUCTS GENERAL MILLS, INC. (US) 2014-08-14 WO disclosed
WO-2014124216-A1 REDUCED SODIUM FOOD PRODUCT GENERAL MILLS, INC. (US) 2014-08-14 WO disclosed
WO-2014124220-A1 REDUCED SODIUM FOOD PRODUCT GENERAL MILLS, INC. (US) 2014-08-14 WO disclosed
WO-2013138871-A1 IMMUNOMODULATORY AGENT AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2013-09-26 WO disclosed
US-20100151000-A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES THE UNIVERSITY OF QUEENSLAND (AU) 2010-06-17 US disclosed
US-20060024691-A1 Novel pathways in the etiology of cancer BUCK INSTITUTE FOR AGE RESEARCH 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041408-A1 SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY NFKBIA, NFRKB, NFKB2 GPR52 393/4885TRPV1 1843/4885ALDH1A1 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.